Treatment of proliferative diseases

• US 20070244071A1
• Filed: 03/07/2007
• Published: 10/18/2007
• Est. Priority Date: 03/07/2006
• Status: Abandoned Application

• Current Assignee: Mount Sinai Hospital (Sinai Health System)
• Original Assignee: Mount Sinai Hospital (Sinai Health System)
• Inventors: Dennis, Jim, Song, Hyun-Joo
• Application Number:
  US11/715,193
• Publication Number:
  US 20070244071A1
• Time in Patent Office: Days
• US Class Current: 514/63
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/655 Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
• CPC Class Codes: A61K 31/695 Silicon compounds

Abstract

The invention relates generally to compositions comprising malonate compounds, and methods and uses of the compositions in the treatment of proliferative diseases. In particular the invention relates to a pharmaceutical composition comprising a compound of the formula I wherein * is ═C or ═O, R1 and R2 independently represent substituted or unsubstituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, carboxamide, carboxylic ester, phosphono, a substituted or unsubstituted aryl group fused to a cycloalkyl group, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers, excipients, and vehicles.

Claims

1. A pharmaceutical composition comprising a compound of the formula I

wherein * is ═

C or ═

O, R1 and R2 independently represent substituted or unsubstituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, carboxamide, carboxylic ester, phosphono, a substituted or unsubstituted aryl group fused to a cycloalkyl group, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers, excipients, and vehicles.

2. A pharmaceutical composition according to claim 1 wherein R1 represents:

a) hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkylene, alkoxy, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, nitro, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, or carboxamide;

b) hydrogen, substituted or unsubstituted alkyl, alkenyl, alkoxy, amino, imino, azido, thiol, thioalkyl, nitro, cyano, halo, silyl, or carboxyl;

c) hydrogen or substituted or unsubstituted alkyl;

d) C₁-C₃ alkyl substituted with one or more halo;

or

e) methyl substituted with one, two, or three halo.

3. A pharmaceutical composition according to claim 1 wherein R2 represents —

NR15 wherein R15 is —

R16R17 wherein R16 is substituted or unsubstituted C₁-C₆ alkyl, and R17 is substituted or unsubstituted aryl.

4. A pharmaceutical composition according to claim 3 wherein R16 is methyl, ethyl, or propyl, and R17 is substituted or unsubstituted phenyl.

5. A pharmaceutical composition according to claim 1 wherein R2 represents —

NR15 wherein R15 is a substituted or unsubstituted heterocylic with 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms or phenyl substituted with bromo, chloro, or substituted C₁-C₃-alkyl.

6. A pharmaceutical composition according to claim 1 wherein R2 represents:

a) substituted or unsubstituted aryl fused to a cycloalkyl;

b) substituted or unsubstituted phenyl fused with a cycloalkyl having 3 to 6 carbon atoms;

c) substituted or unsubstituted phenyl fused with a cyclopropyl, cyclobutyl or cyclopentyl;

d) phenyl fused to cyclopentyl wherein the phenyl is substituted with halo, alkyl, or oxy.

7. A pharmaceutical composition according to claim 1 wherein * is ═

C, R1 represents hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkylene, alkoxy, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, nitro, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, or carboxamide, and R2 represents —

NR15 wherein R15 is —

R16R17 wherein R16 is C₁-C₆ alkyl, and R17 is substituted or unsubstituted aryl.

8. A pharmaceutical composition according to claim 7 wherein R1 is substituted C₁-C₆ alkyl and R2 is NR15 wherein R15 is —

R16R17 wherein R16 is C₁-C₆ alkyl and R17 is substituted or unsubstituted aryl.

9. A pharmaceutical composition according to claim 1 wherein R1 is methyl substituted with one, two or three fluoro and R2 is NR15 wherein R15 is —

R16R17 wherein R16 is C₁-C₃ alkyl and R16 is aryl optionally substituted with hydroxyl, halo, alkyl, alkenyl, alkynyl, alkylene, alkoxy, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, nitro, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, or carboxamide.

10. A pharmaceutical composition according to claim 1 wherein * is ═

C, R1 represents hydrogen, substituted or unsubstituted alkyl, alkenyl, alkoxy, amino, imino, azido, thiol, thioalkyl, nitro, cyano, halo, silyl, or carboxyl and R2 represents —

NR15 wherein R15 is an optionally substituted heterocylic with 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms.

11. A pharmaceutical composition according to claim 10 wherein * is ═

C, R1 represents hydrogen or substituted or unsubstituted alkyl and R2 represents —

NR15 wherein R15 is substituted or unsubstituted 1,3,4-oxadiazolyl or R15 is an 1,3,4-oxadiazole substituted with optionally substituted alkyl, alkenyl, alkynyl, alkylene, alkoxy, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, nitro, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl, carbamoyl, or carboxamide.

12. A pharmaceutical composition according to claim 1 wherein * is ═

O, R1 represents hydrogen, substituted or unsubstituted alkyl or alkoxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, nitro, cyano, halo, silyl, carboxyl, carbonyl, or carbamoyl, and R2 is a substituted or unsubstituted aryl fused to a cycloalkyl having 3 to 6 carbon atoms.

13. A pharmaceutical composition according to claim 12 wherein R1 represents hydrogen or substituted or unsubstituted alkyl and R2 is substituted or unsubstituted phenyl fused to a cycloalkyl having 3 to 6 carbon atoms.

14. A pharmaceutical composition according to claim 13 wherein R2 is substituted phenyl fused to cyclopropyl or R2 is phenyl substituted with halo, ═

O, alkyl, or alkoxy, fused to cyclopropyl at positions 2 to 3.

15. A pharmaceutical composition according to claim 1 wherein R1 is —

NH—

CH₂CH₂-Ph, R2 is —

CF₃, and/or, (ii) R1 is an oxadiazolyl substituted with chlorophenyl, when R2 is hydrogen.

16. A pharmaceutical composition according to claim 1 wherein a compound of the formula I is a compound listed in Table 1.

17. A pharmaceutical composition according to claim 1 wherein a compound of the formula I has a structure of a diethyl 2 (anilinomethylene) malonate compound or derivative thereof.

18. A method for treating a proliferative disease comprising administering to a subject in need of such treatment a composition according to claim 1.

19. A method according to claim 18 wherein the proliferative disease is cancer, tumor invasion, tumor growth, and/or tumor metastasis.

20. A method of enhancing TGFβ

dependent Smad2/3 translocation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition according to claim 1.